Compare TEAM & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TEAM | ILMN |
|---|---|---|
| Founded | 2002 | 1998 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.9B | 21.8B |
| IPO Year | 2015 | 2000 |
| Metric | TEAM | ILMN |
|---|---|---|
| Price | $99.20 | $161.70 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 22 | 17 |
| Target Price | ★ $169.18 | $124.24 |
| AVG Volume (30 Days) | ★ 6.5M | 1.8M |
| Earning Date | 04-30-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 15.52 | ★ 170.87 |
| EPS | N/A | ★ 0.87 |
| Revenue | ★ $5,215,304,000.00 | $4,343,000,000.00 |
| Revenue This Year | $24.65 | $6.47 |
| Revenue Next Year | $17.67 | $5.58 |
| P/E Ratio | ★ N/A | $193.02 |
| Revenue Growth | ★ 19.66 | N/A |
| 52 Week Low | $56.01 | $82.60 |
| 52 Week High | $222.52 | $177.22 |
| Indicator | TEAM | ILMN |
|---|---|---|
| Relative Strength Index (RSI) | 56.96 | 63.64 |
| Support Level | $65.78 | $116.54 |
| Resistance Level | $174.32 | N/A |
| Average True Range (ATR) | 6.48 | 6.46 |
| MACD | 0.72 | 1.38 |
| Stochastic Oscillator | 46.17 | 58.00 |
Atlassian produces software that helps teams work together more efficiently and effectively. The company provides project planning and management software, collaboration tools, and IT help desk solutions. The company operates in four segments: subscriptions (term licenses and cloud agreements), maintenance (annual maintenance contracts that provide support and periodic updates and are generally attached to perpetual license sales), perpetual license (upfront sale for indefinite usage of the software), and other (training, strategic consulting, and revenue from the Atlassian Marketplace app store). Atlassian was founded in 2002 and is headquartered in Sydney.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.